Replies to post #200628 on Biotech Values

[DewDiligence]

(JNJ)—PFE launching US Remicade FoB in November ~15% discount:

http://finance.yahoo.com/news/pfizer-announces-u-availability-biosimilar-200500747.html

INFLECTRA will be introduced at a 15% discount to the current wholesaler acquisition cost (WAC) of REMICADE, its reference product. WAC is not inclusive of discounts to payers, providers, distributors and other purchasing organizations.

[DewDiligence]

FDA approves Renflexis—a Remicade FoB from Samsung/MRK:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761054

Please see #msg-118427495 for partnering details on Samsung Bioepis’ FoB programs.

PFE/Celltrion already has an FDA-approved Remicade FoB called Inflectra (#msg-121701314).